Aurobindo Pharma Limited (BOM:524804)
1,145.60
+23.95 (2.14%)
At close: Jan 22, 2026
Aurobindo Pharma Revenue
Aurobindo Pharma had revenue of 82.86B INR in the quarter ending September 30, 2025, with 6.28% growth. This brings the company's revenue in the last twelve months to 325.14B, up 7.33% year-over-year. In the fiscal year ending March 31, 2025, Aurobindo Pharma had annual revenue of 317.24B with 9.39% growth.
Revenue (ttm)
325.14B
Revenue Growth
+7.33%
P/S Ratio
2.05
Revenue / Employee
11.74M
Employees
27,707
Market Cap
665.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 317.24B | 27.22B | 9.39% |
| Mar 31, 2024 | 290.02B | 41.46B | 16.68% |
| Mar 31, 2023 | 248.55B | 14.00B | 5.97% |
| Mar 31, 2022 | 234.55B | -13.19B | -5.32% |
| Mar 31, 2021 | 247.75B | 16.76B | 7.26% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 10.25T |
| Life Insurance Corporation of India | 9.14T |
| State Bank of India | 3.57T |
| HDFC Bank | 2.85T |
| Larsen & Toubro | 2.76T |
| Tata Consultancy Services | 2.61T |
| Bharti Airtel | 1.95T |
| ICICI Bank | 1.91T |
Aurobindo Pharma News
- 3 days ago - Pharma sector stocks fall today: Glenmark Pharma drops 1.38%, Aurobindo Pharma downm 1.25%, Sun Pharma falls 0.87, Dr. Reddy’s Lab down 0.48% - Business Upturn
- 22 days ago - Aurobindo Pharma acquires branded non-oncology prescription business of Khandelwal Labs' for Rs 325 crore - The Times of India
- 22 days ago - Aurobindo Pharma arm acquires Khandelwal Labs’ non-oncology business for Rs 325 crore - Business Upturn
- 4 weeks ago - Aurobindo Pharma to acquire additional 20% stake in China JV Luoxin Aurovitas for $5.1 million - Business Upturn
- 5 weeks ago - Aurobindo Pharma receives Form 483 with five observations after US FDA inspection at Unit-IV facility - Business Upturn
- 6 weeks ago - Aurobindo Pharma’s subsidiary receives US FDA Form 483 with three procedural observations after Telangana facility inspection - Business Upturn
- 7 weeks ago - JSW Steel, Kotak Mahindra & more: Top stocks to buy today — Check list - The Times of India
- 2 months ago - Aurobindo Pharma receives US FDA clearance for Unit-I; Warning letter officially closed - Business Upturn